Friday, December 6, 2024

CATEGORY

EFPIA

US and China Surge Ahead as Europe’s Pharma R&D Growth Lags

Key TakeawaysEurope's pharmaceutical productivity outpaces the general economy in all studied member states. The growing R&D investment gap requires immediate strategic action to...

New Guidelines for EU Joint Clinical Assessment Set to Streamline Health Technology Evaluations

Key TakeawaysEmbrace diverse evidence synthesis techniques to enhance the quality of JCA dossiers. Recognize the importance of ITCs in addressing gaps left by...

EFPIA Urges Reassessment of Urban Wastewater Directive’s Impact on Pharmaceuticals

Key TakeawaysEFPIA raises concerns that the Urban Wastewater Treatment Directive could harm the competitiveness of Europe's pharmaceutical sector and disrupt the supply of...

Balancing Data Anonymisation and Utility in Health Research

Key TakeawaysBalancing privacy and research progress is crucial when reusing health data. The EFPIA's Anonymisation Gradient offers a framework to understand privacy and...

Evaluating the Public Health Impact of Clinical Data Disclosure

Key TakeawaysThe pharmaceutical industry's data disclosure efforts are increasing, but the impact on public health remains uncertain. EFPIA is prioritizing investments in disclosure...

Enhancing Cancer Screening in the EU: Key Insights from Four Countries

Implementing cancer screening programmes in the EU has proven to be a vital step in improving survival rates, quality of life, and reducing treatment...

EFPIA’s Position on the Regulation on the European Health Data Space

The European Federation of Pharmaceutical Industries and Associations (EFPIA) acknowledges the final agreement on the European Health Data Space (EHDS) Regulation as a pivotal...

Clinical Trials Initiative EU-X-CT Aims to Improve Cross-Border Access in Europe

The EU-X-CT Cross-Border Clinical Trials Initiative, co-led by the European Forum for Good Clinical Practice (EFGCP) and the European Federation of Pharmaceutical Industries and...

Call for Increased Budget in FP10

In shaping the next European Framework Programme for Research and Innovation (FP10), 110 European associations representing key RD&I stakeholders urge EU Institutions to significantly...

Urgent Action on Cardiovascular Health Needed

The European Union (EU) faces a crucial opportunity to address cardiovascular disease (CVD) while enhancing competitiveness in the life sciences sector. The High-Level Conference...

EFPIA Calls for Competitiveness Strategy in EU Life Sciences

At this critical moment of political change in Europe, EFPIA is asking EU leaders to collaborate with the industry to create opportunities for the...

Unequal Medicine Access Across Europe: EFPIA Report Highlights Disparities and Calls for Action

New data from the European Federation of Pharmaceutical Industries and Associations (EFPIA) reveals multiple factors leading to unequal medicine access across Europe. On average,...

Value of Regulatory Data Protection in European Competitiveness

New data demonstrates the value of regulatory data protection (RDP) and its impact on European competitiveness and patient access to medicines. The European Federation...

Pharmaceutical Trade Associations Applaud WHO’s Recognition of EMRN and FDA as Listed Authorities

Pharmaceutical trade associations have applauded the World Health Organization (WHO) for recognizing the European Medicines Regulatory Network (EMRN) and the United States Food and...

Enhancing Patient Involvement in Health Technology Assessments Across Europe

Across Europe, while most countries utilize health technology assessment (HTA) to evaluate the clinical and economic evidence of medications for reimbursement through public healthcare...

Latest news